Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2006 Aug;21(4):639-44.
doi: 10.3346/jkms.2006.21.4.639.

Comparison of serum beta 2-microglobulin and 24 hour urinary creatinine clearance as a prognostic factor in multiple myeloma

Jae-Pil Yun  1 , Cheolwon Suh, Eunkyoung Lee, Jai Won Chang, Won Seok Yang, Jung Sik Park, Su-Kil Park
Affiliations
Comparative Study

Comparison of serum beta 2-microglobulin and 24 hour urinary creatinine clearance as a prognostic factor in multiple myeloma

Jae-Pil Yun et al. J Korean Med Sci. 2006 Aug.

Abstract

A new staging system for multiple myeloma (MM) has utilized serum concentrations of beta2-microglobulin (Sbeta2M) and albumin as important prognostic factors for survival. Since Sbeta2M is an indicator of glomerular filtration rate, we compared the prognostic values of Sbeta2M and 24-hr urinary creatinine clearance (Ccr) in patients with MM. We retrospectively reviewed the records of 170 MM patients from January 1996 to November 2003 whose 24-hr urinary Ccr was available at the time of diagnosis. We found that pretreatment Sbeta2M was inversely related to Ccr (Spearman's correlation coefficient=-0.787). In univariate analysis, the hazard ratio (HR) of death was 1.043 (p<0.001) for Sbeta2M and 0.985 (p<0.001) for Ccr. Multivariate analysis showed that Sbeta2M (HR 1.030, p=0.010) and Ccr (HR 0.993, p=0.059) were significant prognostic factors in patients' survival. In conclusion, 24-hr urinary Ccr may be utilized for staging of patients with MM.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Relationship of beta 2-microglobulin and 24 hr urinary creatinine clearance before chemotherapy.
Fig. 2
Fig. 2
Survival curves according to DS stage (A) and SWOG stage (B) with serum beta 2-microglobulin and serum albumin.
Fig. 3
Fig. 3
Survival curves according to new staging system with Ccr and serum albumin.
See this image and copyright information in PMC

References

    1. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–854. - PubMed
    1. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ Southwest Oncology Group. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol. 2003;122:441–450. - PubMed
    1. Cuzick J, Cooper EH, MacLennan IC. The prognostic value of serum beta 2-microglobulin compared with other presentation features in myelomatosis. Br J Cancer. 1985;52:1–6. - PMC - PubMed
    1. Alexanian R, Barlogie B, Fritsche H. Beta 2-microglobulin in multiple myeloma. Am J Hematol. 1985;20:345–351. - PubMed
    1. Scarffe JH, Anderson H, Palmer MK, Crowther D. Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma. Eur J Cancer Clin Oncol. 1983;19:1361–1364. - PubMed

Publication types